Catalent aims to boost drug delivery through industry-academia partnership

- Last updated on GMT

Boosting communication between industry and academia is the way to advance drug delivery, says Catalent
Boosting communication between industry and academia is the way to advance drug delivery, says Catalent
Catalent has established a new institute in a bid to advance drug delivery by creating links between industry and academia.

The association – named the Applied Drug Delivery Institute – will provide training programmes, help establish partnerships between universities and business, and will work with regulatory bodies in an effort to solve industry-wide issues.

In a statement, senior VP of research and development (R&D) Kurt Nielsen said: “The mission of the Catalent Applied Drug Delivery Institute is to bring better treatments to market by advancing the development and adoption of applied drug delivery technologies.

Rao Tatapudy, VP of scientific affairs added: “We look forward to a continuous series of successful collaborations as the institute’s activities unfold.”

The firm launched the new organisation during a press conference at AAPS, where we spoke to the programme leaders about the reasons behind the move, the current happenings and what’s to come.

Read the article on next week’s Outsourcing-Pharma.com

Related news

Show more

Related products

VDS groß

Meet the challenges of complex injectables

Vetter Pharma International GmbH | 07-Nov-2017 | Technical / White Paper

In the time it takes from the exciting discovery phase to the rigorous demands of a commercial launch, unexpected scientific and technical challenges can...

lyo_vials

Process Development for Lyophilized Products

Baxter BioPharma Solutions | 30-Oct-2017 | Application Note

Baxter approaches formulation and process development with the intention of identifying the failure points for the product. Knowing where the product fails...

Ocopeptides

Advancing therapeutics for myeloma

Recipharm AB | 04-Sep-2017 | Case Study

Multiple myeloma is the second most common blood cancer in the world and despite survival rates increasing over the last decade, there remains a requirement...

Related suppliers